Project Grant R01CA315861
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $565K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Cancer Institute awarded Mayo Clinic a cooperative agreement totaling $688,661 on June 9, 2026, to develop and validate cell-free DNA approaches for prospective detection and monitoring of malignant peripheral nerve sheath tumors (MPNST) and their precursor lesions in neurofibromatosis type 1 (NF1) patients under the Cancer Detection and Diagnosis Research program (CFDA 93.394). Mayo Clinic will conduct three integrated research objectives: determining whether integrative...
- The National Cancer Institute awarded Mayo Clinic $154,590 on January 10, 2026, for DNA aptamers as tools for toxin delivery to glioblastoma under the Cancer Research Manpower program (CFDA 93.398). The award funds research to develop DNA aptamer-drug conjugates (APDCs) that deliver monomethyl auristatin E (MMAE) toxin to glioblastoma tumors while overcoming blood-brain-barrier penetration and intratumoral heterogeneity obstacles. Aim 1 will identify glioblastoma-specific MMAE-conjugated DNA...
- The National Institutes of Health National Cancer Institute awarded $687,314 to Mayo Clinic Jacksonville on July 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate senescence and resistance mechanisms in glioblastoma and to develop combination therapeutic strategies that overcome drug resistance. The funded research examines how glioblastomas develop resistance to mitotic kinase and kinesin inhibitors (ispinesib, alisertib, volasertib, and etoposide) through...
- The National Institute of Neurological Disorders and Stroke awarded Mayo Clinic $219,510 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop noninvasive cell-free DNA biomarkers for early detection and treatment monitoring of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1. The research will integrate cell-free DNA epigenomic features—including methylation patterns and...
- The National Cancer Institute awarded Mayo Clinic Jacksonville $127,983 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support mechanistically guided immunometabolic CAR-TIL therapy research for glioblastoma. The award funds development and evaluation of dual-engineered ME1-armored anti-PD-L1 CAR tumor-infiltrating lymphocytes in combination with intracranial administration of clemastine and bexarotene to address tumor heterogeneity and immune suppression in...
- The National Cancer Institute awarded Mayo Clinic $667,710 on March 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized Phase 2 trial evaluating blood-based tumor and immune markers for risk stratification and treatment response monitoring in oligometastatic castration-sensitive prostate cancer. The project integrates prostate cancer-derived extracellular vesicles and circulating tumor DNA as blood markers to identify patients who will benefit from...
- The National Cancer Institute awarded Emory University $402,401 on May 6, 2026, for development of an F-18 imaging agent to measure glioma IDH1 mutant expression under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The funded work develops a positron emission tomography tracer to non-invasively measure mutated cytosolic NADP+-dependent isocitrate dehydrogenase (IDH1) activity in low-grade glioma and secondary glioblastoma multiforme. IDH1 mutations occur in more than 70...
- The National Cancer Institute awarded Mayo Clinic Jacksonville $620,671 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a bioresorbable implant for local delivery of chemotherapy to aggressive meningiomas. The project addresses treatment limitations in meningioma management. Meningiomas are the most common adult central nervous system tumors, with over 36,000 diagnosed annually in the United States. Current treatment—maximal safe surgical resection...
- The National Institute of Neurological Disorders and Stroke awarded Mayo Clinic Jacksonville $599,699 on July 14, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop chimeric antigen receptor T-cell and tumor-infiltrating lymphocyte immunotherapies targeting glioblastoma. The research applies a "double-hit" strategy combining two adoptive T-cell therapies administered via Ommaya reservoir to bypass the...
- The National Cancer Institute awarded The Medical College of Wisconsin, Inc. $602,121 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 1, 2026, to develop and validate advanced radio-pathomic mapping techniques that predict pathological tumor characteristics in glioblastoma using standard clinical MRI. The research addresses non-enhancing tumor regions that extend beyond visible MRI enhancement and harbor resistant cells serving as recurrence reservoirs, regions...